Exane BNP Paribas Starts GlaxoSmithKline (GSK) at Underperform
Get Alerts GSK Hot Sheet
Price: $42.99 --0%
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 1
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 1
Join SI Premium – FREE
Exane BNP Paribas initiated coverage on GlaxoSmithKline (NYSE: GSK) with an Underperform rating.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $46.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WuXi Biologics Reports Solid 2023 Annual Results
- HSBC starts Spotify (SPOT) at buy, cites significant opportunities
- Oppenheimer Starts Xeris Pharmaceuticals (XERS) at Outperform, 'successful commercial execution will continue to drive top-line growth'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!